We are studying the effects of a new treatment combining V940 with pembrolizumab for patients with resectable stage II to IIIB lung cancer. The goal is to see if this combination improves disease-free survival compared to a placebo.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, which includes several subtypes. It typically grows and spreads more slowly than small cell lung cancer and can cause symptoms like persistent cough, chest pain, and difficulty breathing.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
